Whole-Body ⁶⁸Ga-FAPI PET/CT in Cavernous Sinus Syndrome: A Prospective Comparison With ¹⁸F-FDG PET/CT
NCT07917858, Active not recruiting, Post Graduate Institute of Medical Education and Research, Chandigarh
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Whole-Body ⁶⁸Ga-FAPI PET/CT in Cavernous Sinus Syndrome: A Prospective Comparison With ¹⁸F-FDG PET/CT | ClinicalTrials.gov |
| NCT number | NCT07917858 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Enrollment | 21 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh | ClinicalTrials.gov |
| Conditions | Cavernous Sinus Syndrome | ClinicalTrials.gov |
| Interventions | FAPI tracer, FDG-PET | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Diagnostic performance of ⁶⁸Ga-FAPI PET/CT for detection of cavernous sinus lesions compared with paired ¹⁸F-FDG PET/CT | Baseline (prior to initiation of definitive therapy; both PET/CT examinations performed within 6 days of each other). | Comparison of cavernous sinus lesion detection rates between whole-body ⁶⁸Ga-FAPI PET/CT and paired ¹⁸F-FDG PET/CT on a lesion basis using the McNemar test. A lesion is considered positive when tracer uptake exceeds adjacent background | ClinicalTrials.gov |
| Secondary | Comparison of lesion target-to-background ratio (TBR) between ⁶⁸Ga-FAPI PET/CT and ¹⁸F-FDG PET/CT | Baselines | Comparison of lesion TBR calculated as lesion SUVmax divided by background brain SUVmean for paired lesions. | ClinicalTrials.gov |
| Secondary | Comparison of lesion SUVmax between ⁶⁸Ga-FAPI PET/CT and ¹⁸F-FDG PET/CT | Baseline | Comparison of maximum standardized uptake value (SUVmax) of paired cavernous sinus lesions between the two PET tracers. | ClinicalTrials.gov |
| Secondary | Proportion of participants in whom ⁶⁸Ga-FAPI PET/CT identified an alternative biopsy site | Baseline | Percentage of participants in whom whole-body ⁶⁸Ga-FAPI PET/CT identified a safer and more accessible contiguous or extracranial lesion suitable for tissue diagnosis instead of direct cavernous sinus biopsy. | ClinicalTrials.gov |
| Secondary | Detection of clinically relevant extracranial disease by whole-body ⁶⁸Ga-FAPI PET/CT | Baseline | Number of participants with disease-related extracranial lesions identified on whole-body ⁶⁸Ga-FAPI PET/CT | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)